ArticleFrontiers in drug safety and regulation2025
Federated learning: a privacy-preserving approach to data-centric regulatory cooperation.
Article in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comprehensive overview of AI methodologies in nano-drug delivery Optimization and Design.NPJ precision oncology · 2026Review
- Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group.Drug safety · 2026Article
- Review of Progress of AI in Biomimetics: From Biological Patterns to Closed-Loop Discovery.Biomimetics (Basel, Switzerland) · 2026Review
- Deep learning in multi-omics integration for gastrointestinal cancer biomarker discovery.Frontiers in oncology · 2026Review
- GPCR signaling systems facilitate precision interventions for multi-oncology therapy.Frontiers in systems biology · 2026Review
- Artificial intelligence in oncology: Current status and possibilities (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory agencies aim to ensure the safety and efficacy of medical products but often face legal and privacy concerns that hinder collaboration at the data level. In this paper, we propose federated learning as an innovative method to enhance data-centric collaboration among regulatory agencies by enabling collaborative training of machine learning models without the need for direct data sharing, thereby preserving privacy and overcoming legal hurdles. We illustrate how Swissmedic, the Swiss Agency for Therapeutic Products, together with its partner agencies, proposes to use federated learning to improve TRICIA, an AI tool for assessing incoming reports of serious incidents related to medical devices. This approach enables the development of robust, generalisable risk assessment models that can potentially improve current processes. A proof of concept was deployed and thoroughly tested during the 14th Global Summit on Regulatory Science using synthetic data with participants from Swissmedic, the U.S. Food and Drug Administration (FDA), and the Danish Medicines Agency (DKMA), with promising initial results. This innovation has the potential to serve as a roadmap for other regulators to adopt similar approaches to optimize their own regulatory processes, contributing to a more integrated and efficient regulatory environment worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.